• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

In early STEMI patients, prehospital fibrinolysis is non-inferior to PCI

bys25qthea
March 13, 2013
in Cardiology, Chronic Disease, Surgery
Reading Time: 4 mins read
Share on FacebookShare on Twitter

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: CC/JHeauser

1. For early STEMI patients who could not undergo timely PCI within 1 hour, prehospital fibrinolysis coupled with coronary angiography was non-inferior to PCI.

2. Fibrinolytic therapy was associated with an increased risk of stroke and intracranial hemorrhage.

This multi-center randomized control study randomized patients with early STEMI who could not receive PCI within 1 hour of symptom onset, to prehospital fibrinolysis with early coronary angiography, or PCI.  There was no difference in the primary endpoint, but there was an increased risk of stroke and intracranial hemorrhage in patients who had received fibrinolysis treatment. The standard of care is for patients with STEMI to receive PCI within 1 hour of symptoms. Although many studies have shown PCI to be superior to fibrinolysis, fibrinolysis continues to be used for reperfusion, largely due to lack of access to primary PCI. This study suggests that fibrinolysis continues to be a suitable alternative to PCI if a PCI-capable hospital cannot be reached within an hour.

RELATED REPORTS

The preoperative combination of evolocumab and rosuvastatin may not reduce major adverse cardiovascular events

Late ventricular fibrillation following myocardial infarction is associated with increased risk of 1-year mortality

2 Minute Medicine Rewind January 5, 2026

As this was a multi-center trial that included elderly patients, the results are generalizable. One major limitation is that the study was not adequately powered to demonstrate how different age groups were affected by fibrinolysis vs. PCI.  Also, the follow-up time was short, and whether the outcomes are similar in the long term remains unknown. Another limitation of this study is that much of PCI technology has advanced since this study was concluded: drug-eluting stents have become much safer and have a much lower risk of thrombosis. Future studies will need to determine whether prehospital fibrinolysis coupled with timely coronary angiography is still non-inferior to the new generation of PCI technology in patients who could not receive PCI within one hour of symptom onset.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

[/tab]

[tab]

Image: CC/JHeauser

1. For early STEMI patients who could not undergo timely PCI within 1 hour, prehospital fibrinolysis coupled with coronary angiography was non-inferior to PCI.

2. Fibrinolytic therapy was associated with an increased risk of stroke and intracranial hemorrhage.

This [randomized controlled] study: compared outcomes of 1892 patients who presented to a hospital with an early acute ST-elevation myocardial infarction (STEMI) and who could not receive PCI within the first hour of symptoms.  Patients were randomized to either percutaneous coronary intervention (PCI) or prehospital fibrinolysis with tenecteplase, clopidogrel and enoxaparin followed by timely coronary angiography. The primary endpoint was a composite of 30-day all-cause mortality, shock, congestive heart failure, or reinfarction.

The incidence of the primary endpoint was not significantly different in patients who received prehospital fibrinolysis vs. those who received PCI (12.4% vs. 14.3%, p=0.21). However, there was an increase in the number of strokes and intracranial hemorrhages in those that received fibrinolysis (1% vs. 0.2%, p=0.04), higher in the elderly population. Decreasing the dosage of fibrinolytics by half for elderly patients eliminated any differences in the risk of intracranial hemorrhages.

In sum: This multi-center randomized control study randomized patients with early STEMI who could not receive PCI within 1 hour of symptom onset, to prehospital fibrinolysis with early coronary angiography, or PCI.  There was no difference in the primary endpoint, but there was an increased risk of stroke and intracranial hemorrhage in patients who had received fibrinolysis treatment. The standard of care is for patients with STEMI to receive PCI within 1 hour of symptoms. Although many studies have shown PCI to be superior to fibrinolysis, fibrinolysis continues to be used for reperfusion, largely due to lack of access to primary PCI. This study suggests that fibrinolysis continues to be a suitable alternative to PCI if a PCI-capable hospital cannot be reached within an hour.

As this was a multi-center trial that included elderly patients, the results are generalizable. One major limitation is that the study was not adequately powered to demonstrate how different age groups were affected by fibrinolysis vs. PCI.  Also, the follow-up time was short, and whether the outcomes are similar in the long term remains unknown. Another limitation of this study is that much of PCI technology has advanced since this study was concluded: drug-eluting stents have become much safer and have a much lower risk of thrombosis. Future studies will need to determine whether prehospital fibrinolysis coupled with timely coronary angiography is still non-inferior to the new generation of PCI technology in patients who could not receive PCI within one hour of symptom onset.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

By Jeremy Chan and Mitalee Patil

More from this author: Artifical pancreas lowers the risk of overnight hypoglycemia in children, Selumetinib increases the uptake of radioiodine in patients with metastatic thyroid cancer refractory to radioiodine

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: angiographyfibrinolysisheart attackmyocardial infarctionPCISTEMI
Previous Post

Primary care and specialists have comparable outcomes in treating Sleep Apnea

Next Post

Ischemic heart disease increases linearly with radiotherapy for breast cancer

RelatedReports

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Cardiology

The preoperative combination of evolocumab and rosuvastatin may not reduce major adverse cardiovascular events

January 12, 2026
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Cardiology

Late ventricular fibrillation following myocardial infarction is associated with increased risk of 1-year mortality

January 12, 2026
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Weekly Rewinds

2 Minute Medicine Rewind January 5, 2026

January 13, 2026
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Cardiology

The efficacy 3 months of dual antiplatelet therapy is similar to 12 months in patients with acute coronary syndrome

January 12, 2026
Next Post

Ischemic heart disease increases linearly with radiotherapy for breast cancer

Family presence during CPR associated with lower rates of emotional trauma

Family presence during CPR associated with lower rates of emotional trauma

Nonemergent percutaneous coronary intervention safe without on-site cardiac surgery services

Nonemergent percutaneous coronary intervention safe without on-site cardiac surgery services

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
  • Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.